By Mill Chart
Last update: Nov 17, 2023
Our stock screening tool has identified GILEAD SCIENCES INC (NASDAQ:GILD) as an undervalued gem with strong fundamentals. NASDAQ:GILD boasts decent financial health and profitability while maintaining an attractive price point. We'll break it down further.
ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NASDAQ:GILD has earned a 7 for valuation:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:GILD scores a 8 out of 10:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:GILD has achieved a 5 out of 10:
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:GILD was assigned a score of 4 for growth:
Our Decent Value screener lists more Decent Value stocks and is updated daily.
Check the latest full fundamental report of GILD for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
GILEAD SCIENCES INC
NASDAQ:GILD (4/26/2024, 7:00:00 PM)
After market: 65.5 +0.08 (+0.12%)65.42
+0.15 (+0.23%)
Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors.
GILD earnings call for the period ending March 31, 2024.
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gilead Sciences (NASDAQ:GILD) just reported results for the first quarter of 20...
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top S&P500 gainers and losers in today's after hours session.
Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury.
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).